Perfil da empresa · Healthcare

Pfizer Inc

PFE · EUA
Indústria
Pharmaceuticals
Bolsa
EUA
País / Região
USA
Data do IPO
22 de junho de 1942
Funcionários
75.000
Preço atual
$25.21
Ao vivo · 18 de junho de 2026
Pontuação de Crescimento Baillie
40/100
Fraco
Valor intrínseco · Faixa em três níveis Preço atual $25.21 Ao vivo · Dentro da faixa de valor intrínseco justo

Faixa de valuation composta · conservador $16–$19 / justo $24–$28 / otimista $32–$36. A $25.21, Dentro da faixa de valor intrínseco justo.

Na publicação $25.85 (25 de maio de 2026)

Ainda não há análises sobre este ativo no seu idioma.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Valor de mercadoUS$ 147,73 bi
Receita (TTM)US$ 63,32 bi
EBITDAUS$ 25,46 bi
Margem líquida11,83%
ROE8,31%
P/L (TTM)19,79
P/L projetado8,79
PEG3,77
LPAUS$ 1,31
Dividend yield6,61%
Faixa de 52 semanasUS$ 21,97 – US$ 28,28
Preço-alvo dos analistasUS$ 29,19
Recomendação dos analistas3.6 / 5

Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.

História

Em breveEsta seção está sendo preenchida — volte em breve.

Posição no setor

Em breveEsta seção está sendo preenchida — volte em breve.